Connaught/Pasteur-Merieux' ALVAC-HIV canarypox AIDS vaccine to enter new NIAID AVEG trials.
Executive Summary
CONNAUGHT/PASTER-MERIEUX' ALVAC-HIV AIDS VACCINE IS ONE OF THREE investigational AIDS vaccines beginning clinical trials under the auspices of the National Institute of Allergy & Infectious Disease AIDS Vaccine Evaluation Group, NIAID announced June 13. ALVAC-HIV (vCP205) is a live recombinant vaccine made from a weakened canarypox virus that may be safer than previous cowpox virus vaccines because it "does not grow in human cells," NIAID said.